Project Details
Description
A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
| Status | Finished |
|---|---|
| Effective start/end date | 10/1/16 → 2/28/25 |
Funding
- NRG ONCOLOGY FOUNDATION, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.